心力衰竭和肥胖:新的见解,导致新的治疗模式
Laura M G Meems1, Dirk J van Veldhuisen2, Naveed Sattar3
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. l.m.g.meems@umcg.nl.
Nature reviews. Cardiology
|July 28, 2025
概括
肥胖显著增加心力衰竭的风险,特别是对于HFpEF. 新的减肥药强调了肥胖和心力衰竭之间的关键联系,需要更好的管理策略.
科学领域:
- 心脏病学 心脏病学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 心力衰竭 (HF) 和肥胖是全球主要的健康问题.
- 肥胖增加了每BMI单位的5-7%的新发性HF发病率,HF的风险更高,具有保存的射出分数 (HFpEF).
- 在历史上,HF与肥胖的联系被低估了,但由于新的减肥药物的好处,现在已经很明显.
研究的目的:
- 审查肥胖对HF发育的影响.
- 探索流行病学和病理生理学链接肥胖和HF.
- 讨论当前和新的管理策略,对HF患者的肥胖.
主要方法:
- 对流行病学数据的文献综述.
- 对病理生理机制的分析.
- 关于生活方式和药物干预的临床证据摘要.
主要成果:
- 肥胖是HF,特别是HFpEF的重要危险因素.
- 病理生理学联系包括炎症,代谢功能障碍和心脏重塑.
- 减肥药物在改善HFpEF患者的结果方面表现有前途.
结论:
- 肥胖和HF之间的关系是明确和临床显著的.
- 心血管医生必须将肥胖管理纳入心血管疾病护理.
- 对心血管疾病中故意减肥的进一步研究是必不可少的.
相关概念视频
Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Heart Failure I: Introduction
55
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
55
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28


